Hepatitis C Virus Genotype 4 Infection Clinical Trial
Official title:
Pilot Study to Assess Efficacy and Safety of a Quadruple Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Non-responders to Pegylated Interferon-Ribavirin Regimen
Success rates, after retreatment with Peg-Interferon/Ribavirin bitherapy, in patients
infected with HCV (hepatitis C virus) genotype 4 and non-responders to a first standard
treatment, are disappointing. The association of Asunaprevir and Daclatasvir in combination
with the standard-of-care bitherapy has been shown to increase the efficacy of the treatment
in non-responders genotype 1-infected patients.
Given the absence of current solutions and urgent therapeutic needs for HCV genotype
4-infected patients previously treated with pegylated Interferon/Ribavirin, this pilot study
aims to evaluate the efficacy and safety of a quadritherapy associating Asunaprevir,
Daclatasvir, pegylated Interferon alpha-2a and Ribavirin, in this very difficult to treat
population.
60 subjects will be enrolled.
The primary endpoint will be the rate of sustained virological response (SVR), defined by an
undetectable HCV RNA, at Week 36 (12 weeks after the end of a 24 weeks quadritherapy).
| Status | Completed |
| Enrollment | 60 |
| Est. completion date | April 2015 |
| Est. primary completion date | February 2015 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Adult =18 years - Infection with HCV genotype 4, confirmed by detectable HCV RNA = 1000 IU/ml at pre-inclusion - Non-responders to a prior treatment with pegylated Interferon and Ribavirin, with non-response being defined as follows: - Null-response: reduction of less than 2 log10 IU/ml of HCV viral load between D0 of the treatment and week 12 - Partial response: reduction of at least 2 log10 IU/ml of HCV viral load between D0 of the treatment and week 12 but detectable HCV RNA at week 12 and week 24 and without an undetectable viral load by the end of treatment - Anti-HCV treatment discontinued for at least the last 3 months - Fibrosis at any stage, with documentation of the presence or absence of cirrhosis at the pre-inclusion visit: - history of liver biopsy showing cirrhosis lesions (METAVIR F4), at any time in the patient's history, and/or - good quality (length = 15 mm and = 6 portal spaces) liver puncture biopsy from less than 18 months to establish the METAVIR, and/or - hepatic impulse elastometry (Fibroscan®) from less than 6 months and of good quality (at least 10 measurements on an incidence with an IQR of less than 30% of the mean elastometry measured and a success rate of 60%) - Body weight = 40 kg and =125 kg - Men and women of child-bearing age and their heterosexual partners must use two adequate contraceptions from 1 month before initiation of treatment up to 7 months after the end of treatment for men and up to 4 months after treatment for women. - Written informed consents (2) signed by the patient and the investigator (on the day of the pre-inclusion at the latest and before any examination required by the study) - Patients with Health insurance (Sécurité Sociale or Couverture Médicale Universelle) Exclusion Criteria: - CHILD B or C cirrhosis or a history of decompensated cirrhosis. If Child A cirrhosis, presence of varices presenting an hemorrhagic risk (grade II with red spots or grade III) on a fibroscopy dating from less than 3 years - Previous HCV therapy including HCV NS3 protease inhibitor, and/or HCV NS5A replication complex inhibitor and/or HCV NS5B polymerase inhibitor - Positive HBs Antigen - Confirmed HIV-1 or HIV-2 infection - Pregnant or breast-feeding women - Severe heart or lung disease - Transplant recipient - Uncontrolled dysthyroidism - Uncontrolled diabetes - Any evolutive ongoing malignant disease, including hepatocellular carcinoma, which will be specifically screened for before inclusion - Consumption of alcohol which, in the opinion of the investigator, will be an obstacle to participation of the patient and to his remaining in the study - Drug addiction which, in the the investigator's opinion, will be an obstacle to the patient's participation and to his or her remaining in the study. Patients included in a programme of substitution with methadone or buprenorphine could be included. The opinion of a consultant in addictology is recommended for patients presenting with current drug use or drug use in the past year. - Patients taking part in another clinical trial during the 30 days preceding inclusion. - Patient under guardianship, trusteeship or judicial protection - Hb < 110 g/L - Platelets < 80 000/mm3 - Polynuclear neutrophils < 1000 /mm3 (for European patients) and < 750 /mm3 (for African patients) - Kidney failure defined by creatinine clearance < 50mL/mn (MDRD formula) - Contra-indication for treatment with Ribavirin including a history of hypersensitivity to Ribavirin or to one of the excipients - Contra-indication for treatment with Daclatasvir or Asunaprevir including a history of hypersensitivity to one of the excipients - Contra-indication to treatment with Interferon including psychiatric contra-indications. A psychiatrist's opinion is compulsory in the following situations : - history of psychiatric disorders requiring hospitalisation of the patient or a consultation with a specialist - treatment with mood stabilizers or antipsychotics during the previous year - history of psychiatric disorders during prior treatment with Interferon alpha - evidence of depression episodes, a risk of suicide, bipolar disorder and/or current behavioral disorders. These patients can only be included after a psychiatric evaluation that specifically authorizes the use of Interferon. - History of previous HCV treatment premature cessation (in the first 6 months) for toxicity. Premature cessation for anemia or neutropenia will be authorized in the absence of the use of erythropoietin or polynuclear neutrophil growth factor, respectively. - Patients with a non-compliance history, who will be at risk of not complying with the study follow-up timetable - Associated treatment likely to interfere with the study drugs |
| Country | Name | City | State |
|---|---|---|---|
| France | Hôpital AVICENNE | Bobigny | |
| France | Hôpital Jean Verdier | Bondy | |
| France | Hôpital de Haut Lévêque | Bordeaux Pessac | |
| France | Hôpital Beaujon | Clichy | |
| France | Centre Hospitalier Intercommunal | Créteil | |
| France | Hôpital Henri Mondor | Créteil | |
| France | Hôpital Albert Michallon | Grenoble | |
| France | Hôpital Claude Huriez | Lille | |
| France | Hôpital Dupuytren | Limoges | |
| France | Hôpital de la Croix Rousse | Lyon | |
| France | Fondation Hôpital Saint Joseph | Marseille | |
| France | Hôpital Saint Eloi | Montpellier | |
| France | Hôpital de Brabois | Nancy | |
| France | Hôpital de l'Hôtel Dieu | Nantes | |
| France | Hôpital de l'Archet | Nice | |
| France | Hôpital de La Source | Orléans | |
| France | Hôpital Cochin | Paris | |
| France | Hôpital Pitié Salpêtrière | Paris | |
| France | Hôpital Saint Antoine | Paris | |
| France | Hôpital Tenon | Paris | |
| France | Hôpital Pontchaillou | Rennes | |
| France | Hôpital Charles Nicolle | Rouen | |
| France | Institut Arnault Tzank | Saint Laurent du Var | |
| France | Hôpital Purpan | Toulouse | |
| France | Hôpital Paul Brousse | Villejuif |
| Lead Sponsor | Collaborator |
|---|---|
| French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | Bristol-Myers Squibb |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | SVR12 Rate | HCV RNA measured 12 weeks after the end of the HCV treatment (Week 36) | Week 36 | |
| Secondary | Number of patients with adverse events | Up to Week 48 | ||
| Secondary | Treatment discontinuations | Number and causes of treatment discontinuations | Up to Week 24 | |
| Secondary | Self-reported symptoms | ANRS AC24 perceived symptoms scale | Day 0, Week 12, Week 36 | |
| Secondary | Patients' adherence | ANRS questionnaire | Week 4, Week 12, Week 24 | |
| Secondary | SVR 24 rate | Undetectable HCV RNA 24 weeks after the end of the HCV treatment | Week 48 | |
| Secondary | HCV viral load | Day 0, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 48 | ||
| Secondary | Number of patients with virological failure under treatment | Patients with detectable HCV viral load at Week 8, or Patients with HCV breakthrough : a) undetectable HCV viral load at Week 8 and detectable at any visit after Week 8 or b) undetectable HCV viral load at any time point before Week 8 and who presents a new confirmed detectable viral load before Week 8 | Up to Week 24 | |
| Secondary | HCV subtypic distribution | Baseline | ||
| Secondary | Proportion of patients with resistance mutations to Asunaprevir and/or Daclatasvir in case of virological failure | Up to Week 48 | ||
| Secondary | Cirrhosis evaluation | For cirrhotic patients : Child-Pugh and MELD scores ; cirrhosis decompensation evaluation on clinical examination | Baseline, Week 12, Week 24, Week 36, Week 48 | |
| Secondary | Insulin resistance : HOMA-IR score | Day 0, Week 36 | ||
| Secondary | Metabolic syndrome parameters | Waist circumference, blood pressure, fasting glucose, triglycerides, HDL cholesterol (composite measure) | Day 0, Week 36 | |
| Secondary | Liver fibrosis | Evolution of liver fibrosis on biological parameters (Fibrotest®) and imaging (Fibroscan®) | Between baseline and Week 48 | |
| Secondary | Polymorphism of the gene of IL28B | Day 0 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02309450 -
Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen
|
Phase 2 |